A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) (SAAVe)

Spirovant Sciences, Inc.

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Cystic Fibrosis

Treatments: Combination Product: SP-101 and doxorubicin Cohort 2; Combination Product: SP-101 and doxorubicin Cohort 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT06526923

CFAAV-001

Details and patient eligibility

About

This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

Full description

This multi-center study is a first-in-human, single ascending dose, Phase 1/2 trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of various dose levels in people with CF who are ineligible or intolerant to CFTR modulator therapy.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males or females, age 18 to 65 years at Screening Visit, inclusive
2. Diagnosis of CF
3. ppFEV1 value between 50-100% (inclusive)
4. Resting oxygen saturation ≥94% on room air by pulse oximetry 5 . Clinically stable CF disease as assessed by the Investigator and not requiring any new class of interventional treatment within the last 3 months prior to Screening

Exclusion criteria

1. Any change in established pulmonary treatment (including antibiotics) within 28 days prior to Screening Visit. However, inhaled beta-agonists can be included within 2 weeks prior to Screening Visit.
2. Clinically significant episode of hemoptysis (>50 mL or ¼ cup or 10 teaspoons per day) within 12 weeks prior to dosing with study drug on Day 1
3. Lung infection with Mycobacterium abscessus associated with a more rapid decline in pulmonary status
4. Currently receiving treatment for active lung infection with Burkholderia cenocepacia or Burkholderia dolosa
5. History of solid organ or hematological transplantation
6. History of clinically significant cirrhosis with or without portal hypertension
7. History of pulmonary hypertension
8. History of cardiotoxicity, a history of known coronary artery disease, and/or existing cardiomyopathy
9. Current active fungal infection (not just a positive culture), acute blood, lung, or bladder infection, clinically significant hepatic or renal dysfunction, and/or viral infection (including human immunodeficiency virus or hepatitis virus B or C) requiring the initiation of new therapy within 30 days prior to Screening
10. History of allergic bronchopulmonary aspergillosis (ABPA)
11. Uncontrolled diabetes mellitus, as evidenced by hemoglobin A1c >9% at Screening
12. Clinically significant laboratory abnormalities at Screening
13. Subjects with any medical condition or abnormal laboratory result that, in the opinion of the Investigator, will interfere with the safe completion of the study
14. Subjects who received any investigational products within 30 days (or 5 therapeutic half-lives, whichever is longer) prior to Screening
15. Subjects who have previously received any gene therapy agent
16. Subjects with known sensitivity to SP-101, doxorubicin or its excipients

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

15 participants in 3 patient groups

Cohort 1

Experimental group

Description:

Single inhalational administration of SP-101 and doxorubicin Dose 1

Treatment:

Combination Product: SP-101 and doxorubicin Cohort 1

Cohort 2

Experimental group

Description:

Single inhalational administration of SP-101 and doxorubicin Dose 2

Treatment:

Combination Product: SP-101 and doxorubicin Cohort 2

Dose Expansion

Experimental group

Description:

Single inhalational administration of SP-101 and doxorubicin Selected Dose

Treatment:

Combination Product: SP-101 and doxorubicin Cohort 1

Combination Product: SP-101 and doxorubicin Cohort 2